Drug Trial Radar · NCT07006246
Utilizing Private Pharmacies to Initiate High-risk Young Individuals on PrEP in South Africa
Last checked: Nov 19, 2026Latest source record: Jun 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,900
Planned (sponsor's estimate)
Start
May 19, 2023
Primary completion
Nov 30, 2025
Study completion Nov 30, 2025
Sponsor
- Lead sponsor
- Professor Francois VenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Bill and Melinda Gates Foundation
- First posted
- Jun 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 35 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a funded implementation study designed to evaluate the efficacy of recruiting and retaining high-risk individuals on pre-exposure prophylaxis (PrEP) within multiple private pharmacies (and online platforms in South Africa)
Conditions
- HIV Infection
Interventions
Tenofovir disoproxil fumarate + lamivudine/emtricitabine (TDF+3TC /FTC)Drug
Tenofovir disoproxil fumarate + emtricitabine/ lamivudine Dosage Formulation: 300 mg / 200 mg (300mg) fixed dose combination tablet Route of Administration: Oral Dosing Instructions: 1 tablet (300/200/ TDF/FTC) daily or (300/300/TDF/3TC) daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of pharmacies providing Prep services over 13 monthsTime frame: 13 Months
- Number of participants accessing PrEP online services over 13 monthsTime frame: 13 Months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ezintsha, a division of Wits Health Consortium
Johannesburg, Gauteng, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.